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Introduction {#jah31594-sec-0004}
============

Prior studies have shown an increased risk of ischemic stroke (IS) after myocardial infarction (MI) that is highest in the first few days after the event.[1](#jah31594-bib-0001){ref-type="ref"} The early IS risk after ST‐segment elevation MI (STEMI) has been shown to be related to left ventricular thrombi, which tend to develop within the first 2 weeks,[2](#jah31594-bib-0002){ref-type="ref"} and has been reduced with reperfusion therapy.[3](#jah31594-bib-0003){ref-type="ref"} In addition, several factors, such as the use of antiplatelets,[4](#jah31594-bib-0004){ref-type="ref"} statins,[4](#jah31594-bib-0004){ref-type="ref"} and anticoagulants,[5](#jah31594-bib-0005){ref-type="ref"}, [6](#jah31594-bib-0006){ref-type="ref"} have contributed to a reduction in the early risk of IS after MI. The presence of cardiac injury in acute coronary syndrome (ACS) may induce cardiac arrhythmias or cause cardiac dysfunction, which in turn may increase the long‐term stroke risk. There is limited evidence, however, on the duration of the elevated IS risk in patients with ACS and whether it is directly related to cardiac injury. We hypothesized that the risk of IS after ACS is significantly higher when there is evidence of cardiac injury, such as in STEMI or non‐STEMI (NSTEMI), than when there is no evidence of cardiac injury, such as in unstable angina (UA).

Methods {#jah31594-sec-0005}
=======

Design {#jah31594-sec-0006}
------

We performed a retrospective analysis using administrative claims data on all hospitalizations and emergency department visits at nonfederal health care facilities in California. Data are publicly available and deidentified with a unique linkage number that allows each patient to be followed up for several years across emergency department encounters and hospitalizations. Each encounter included up to 25 discharge diagnoses that were coded using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9), with labels indicating whether the diagnosis was present before hospital admission or developed during the hospitalization. The ICD‐9 codes, including those for STEMI, NSTEMI, and UA, that we used have been used in prior studies of the same data set[7](#jah31594-bib-0007){ref-type="ref"}, [8](#jah31594-bib-0008){ref-type="ref"}, [9](#jah31594-bib-0009){ref-type="ref"} and have been validated previously.[10](#jah31594-bib-0010){ref-type="ref"} Because the data are publicly available and deidentified, no institutional review board approval was required to perform the analysis.

Population {#jah31594-sec-0007}
----------

The study cohort consisted of all adult patients hospitalized with a primary diagnosis of STEMI (ICD‐9 codes 410.XX‐ 410.6X, 410.8X, 410.9X), NSTEMI (ICD‐9 code 410.7X), or UA (ICD‐9 code 411.1)[11](#jah31594-bib-0011){ref-type="ref"} during the years 2009 and 2010. These dates were chosen to ensure each patient had up to 2 years of follow‐up from their coronary event because the latest data were available up to the year 2011. Because we were interested in the long‐term IS risk after a coronary event, we excluded patients with known cerebrovascular disease before the index hospitalization. As an additional safeguard against missed or faulty claims data, patients with any cerebrovascular disease in 2008 were also excluded.

Main Predictors {#jah31594-sec-0008}
---------------

The primary predictors were STEMI and NSTEMI versus UA. Patients were stratified based on their highest achieved diagnosis during follow‐up, considering the ranking of STEMI to be the highest, followed by NSTEMI and then UA.

Outcomes {#jah31594-sec-0009}
--------

The primary outcome during 2‐year follow‐up was IS, defined as ICD‐9 codes 433.x1, 434.x1, or 436.x in any hospital discharge diagnosis without an accompanying diagnosis of intracerebral hemorrhage (ICD‐9 code 431) or subarachnoid hemorrhage (ICD‐9 code 430). This validated algorithm has sensitivity of 86% and specificity of 95% for IS.[12](#jah31594-bib-0012){ref-type="ref"} The secondary outcome was IS or death during 2‐year follow‐up.

Covariates {#jah31594-sec-0010}
----------

We adjusted for baseline demographics and several covariates that could potentially influence the long‐term risk of IS. Baseline demographics included age, sex, race and ethnicity, and insurance status. Covariates included history of hypertension (ICD‐9 codes 401.00--405.90), history of diabetes (ICD‐9 code 250.XX), history of hyperlipidemia (ICD‐9 code 272.4), smoking history (ICD‐9 code 305.1), history of atrial fibrillation (AF; ICD‐9 code 427.3), history of chronic kidney disease (ICD‐9 code 585.XX), and history of congestive heart failure (CHF; ICD‐9 code 428.0X).

Analytic Plan {#jah31594-sec-0011}
-------------

The study population was characterized using descriptive statistics; categorical variables are presented with counts and frequencies, and continuous variables are presented with means and standard deviations. Time‐to‐event data (eg, IS, mortality) were compared using log‐rank tests and presented as Kaplan--Meier curves. Kaplan--Meier survival analysis was performed to compare the associations between the highest type of ACS and the probability of IS and IS or death over the study period, with log rank to detect significant differences. To account for any patient‐specific and disease‐related factors, a Cox proportional hazards regression model was used with adjustment for age; sex; race and ethnicity; insurance status; and baseline hypertension, diabetes, hyperlipidemia, smoking, CHF, chronic kidney disease, and AF at baseline and during follow‐up. The assumption of proportionality was tested using time‐varying effects. Because the expected IS risk after ACS varies with time based on previous studies of ACS, models accounting for nonproportionality were used.

Unadjusted and adjusted Cox proportional hazards models were used to estimate the associations between the type of ACS and IS risk during 2‐year follow‐up after adjusting for potential confounders. Time‐dependent variables were used to eliminate immortal time bias for patients with changes in ACS status, and baseline values were used for covariates. The models were predefined as follows: Model 1 adjusted for age, sex, and race and ethnicity; model 2 adjusted for age, sex, race and ethnicity, insurance status, history of hypertension, history of diabetes, history of hyperlipidemia, smoking history, history of AF, chronic kidney disease, and history of CHF; model 3 adjusted for age, sex, race and ethnicity, insurance status, history of hypertension, history of diabetes, history of hyperlipidemia, smoking history, history of CHF, chronic kidney disease, and history of AF or subsequent AF during follow‐up, which was represented with a time‐dependent covariate. Statistical analysis was performed using SAS 9.3 (SAS Institute). *P*\<0.05 was considered statistically significant.

Results {#jah31594-sec-0012}
=======

Baseline Demographics {#jah31594-sec-0013}
---------------------

We identified 73 079 patients with a diagnosis of STEMI (n=26 427), NSTEMI (n=39 833), or UA (n=6819) during the study period. The mean age was 66.6±14.4 years, and 61.8% of the patients were male. IS during 2‐year follow‐up occurred in 1956 patients (2.7%); 2.43% (n=641) had STEMI, 3.12% (n=1243) had NSTEMI, and 1.06% (n=72) had UA. Other baseline demographics and clinical characteristics of the study population are listed in Table [1](#jah31594-tbl-0001){ref-type="table-wrap"}.

###### 

Baseline Characteristics of Patients in the Cohort (n=73 079)

  Clinical Characteristic         Value
  ------------------------------- ---------------
  Age, y, mean±SD                 66.6±14.4
  Race and ethnicity (n=71 128)   
  White                           64.3 (45 740)
  Black                           7.2 (5139)
  Hispanic                        19.8 (14 050)
  Asian                           8.7 (6199)
  Sex (% male)                    61.8 (45 117)
  Insurance status (n=73 071)     
  Medicare                        51.2 (37 443)
  Medicaid                        8.6 (6310)
  Private or other                35.0 (25 587)
  Self‐pay                        5.1 (3731)
  Hypertension                    71.5 (52 229)
  Diabetes                        34.2 (25 028)
  Hyperlipidemia                  48.2 (35 243)
  Congestive heart failure        25.9 (18 920)
  AF                              15.0 (10 990)
  Smoking                         19.1 (13 981)
  Chronic kidney disease          22.0 (13 460)
  Unstable angina                 9.3 (6819)
  NSTEMI                          54.5 (39 833)
  STEMI                           36.2 (26 427)
  Ischemic stroke at follow‐up    2.68 (1956)
  Death during follow‐up          8.83 (6450)

Data are shown as percentage (number) except as indicated. AF indicates atrial fibrillation; NSTEMI, non--ST‐segment elevation myocardial infarction; STEMI, ST‐segment elevation myocardial infarction.

Risk of IS With Respect to Type of Initial Event (STEMI, NSTEMI, or UA) {#jah31594-sec-0014}
-----------------------------------------------------------------------

The unadjusted risk of IS over 2 years was higher in patients with NSTEMI (hazard ratio \[HR\] 4.86, 95% CI 3.51--6.72; *P*\<0.001) and STEMI (HR 4.23, 95% CI 3.04--5.90; *P*\<0.001) compared with UA (Figure [1](#jah31594-fig-0001){ref-type="fig"}). In the fully adjusted models that included potential confounders such as AF and CHF, the risk of IS remained elevated with STEMI (HR 4.17, 95% CI 3.00--5.83; *P*\<0.001) and NSTEMI (HR 3.73, 95% CI 2.68--5.19, *P*\<0.001) compared with UA (Table [2](#jah31594-tbl-0002){ref-type="table-wrap"}), and there was no difference in risk between STEMI and NSTEMI.

![Kaplan--Meier curves for ischemic stroke events in different types of acute coronary syndrome (NSTEMI,STEMI, UA), log‐rank test *P*\<0.001. NSTEMI indicates non--ST‐segment elevation myocardial infarction; SNU, STEMI/NSTEMI/Unstable Angina; STEMI, ST‐segment elevation myocardial infarction; UA, unstable angina.](JAH3-5-e002590-g001){#jah31594-fig-0001}

###### 

HRs for IS and Probability for Patients Diagnosed With ACS Between 2009 and 2010

               Risk of IS                      Risk of IS or Death                                              
  ------------ ------------------------------- ------------------------------- -------------------------------- ----------------------------------
  Unadjusted   4.86 (3.51--6.72); *P*\<0.001   4.23 (3.04--5.90); *P*\<0.001   8.62 (6.89--10.79); *P*\<0.001   12.75 (10.18--15.96); *P*\<0.001
  Model 1      4.11 (2.96--5.71); *P*\<0.001   4.27 (3.06--5.95); *P*\<0.001   5.95 (4.74--7.47); *P*\<0.001    11.06 (8.8--13.89); *P*\<0.001
  Model 2      3.68 (2.65--5.12); *P*\<0.001   4.11 (2.94--5.75); *P*\<0.001   4.88 (3.88--6.13); *P*\<0.001    9.99 (7.96--12.57); *P*\<0.001
  Model 3      3.73 (2.68--5.19); *P*\<0.001   4.17 (3.00--5.83); *P*\<0.001   4.95 (3.94--6.22); *P*\<0.001    10.06 (8.0--12.64); *P*\<0.001

Unstable angina was the reference for all models. Model 1 adjusted for age, sex, race and ethnicity. Model 2 adjusted for age; sex; race and ethnicity; insurance status; and baseline hypertension, diabetes, hyperlipidemia, smoking, atrial fibrillation, chronic kidney disease, and congestive heart failure. Model 3 adjusted for age; sex; race and ethnicity; insurance status; and baseline hypertension, diabetes, hyperlipidemia, smoking, congestive heart failure, chronic kidney disease, and atrial fibrillation at baseline and during follow‐up. ACS indicates acute coronary syndrome; HR, hazard ratio; IS, ischemic stroke; NSTEMI, non--ST‐segment elevation myocardial infarction; STEMI, ST‐segment elevation myocardial infarction.

Risk of IS or Death With Respect to Type of Highest Event (STEMI, NSTEMI, or UA) {#jah31594-sec-0015}
--------------------------------------------------------------------------------

The unadjusted risk of IS or death over 2 years was higher in patients with STEMI (HR 12.75, 95% CI 10.18--15.96; *P*\<0.001) and NSTEMI (HR 8.62, 95% CI 6.89--10.79; *P*\<0.001) compared with UA (Figure [2](#jah31594-fig-0002){ref-type="fig"}). In the fully adjusted models that included potential confounders such as AF and CHF, the risk of IS or death remained elevated with STEMI (HR 10.06, 95% CI 8.01--12.64; *P*\<0.001) and NSTEMI (HR 4.95, 95% CI 3.94--6.22; *P*\<0.001) compared with UA (Table [2](#jah31594-tbl-0002){ref-type="table-wrap"}).

![Kaplan--Meier curves for ischemic stroke events or death in different types of acute coronary syndrome (NSTEMI,STEMI, UA), log‐rank test *P*\<0.001. NSTEMI indicates non--ST‐segment elevation myocardial infarction; SNU, STEMI/NSTEMI/Unstable Angina; STEMI, ST‐segment elevation myocardial infarction; UA, unstable angina.](JAH3-5-e002590-g002){#jah31594-fig-0002}

Risk of IS With Time {#jah31594-sec-0016}
--------------------

There was a time‐dependent decrease in the risk of IS after STEMI and NSTEMI. In fully adjusted models, for patients with STEMI, the HR for IS dropped from 3.68 at 1 month to 0.93 at 12 months after the event. Similarly, in fully adjusted models, there was a drop in the HR of IS after NSTEMI from 3.34 at 1 month to 0.99 at 12 months following the event (Figure [3](#jah31594-fig-0003){ref-type="fig"}). The elevated risk of IS after STEMI or NSTEMI was during the first 6 months after the event.

![A, Hazard ratios of ischemic stroke as a function of time after NT (A) and as a function of time after ST (B). LCL, lower confidence level; NT, non--ST‐segment elevation myocardial infarction; ST, ST‐segment elevation myocardial infarction; UCL, upper confidence level.](JAH3-5-e002590-g003){#jah31594-fig-0003}

Other Risk Factors for Stroke After ACS {#jah31594-sec-0017}
---------------------------------------

Other risk factors for IS after ACS in the fully adjusted models (model 3) were age (per 10 years: HR 1.25, 95% CI 1.20--1.32), female sex (HR 1.24, 95% CI 1.13--1.36), black race (compared with white: HR 1.70, 95% CI 1.45--1.99), Asian race (compared with white: HR 1.48, 95% CI 1.29--1.75), Hispanic ethnicity (compared with white non‐Hispanic: HR 1.25, 95% CI 1.10--1.41), chronic kidney disease (HR 1.15, 95% CI 1.02--1.31), diabetes (HR 1.30, 95% CI 1.18--1.43), CHF (HR 1.38, 95% CI 1.25--1.53), and AF (HR 1.58, 95% CI 1.39--1.80) (Table [3](#jah31594-tbl-0003){ref-type="table-wrap"}). In addition, hyperlipidemia (HR 0.72, 95% CI 0.62--0.84) and private insurance (compared with Medicare: HR 0.74, 95% CI 0.64--0.85) were associated with a reduced risk of IS. Other risk factors including history of hypertension, history of hyperlipidemia, and history of smoking were not associated with increased risk of IS.

###### 

Fully Adjusted (Model 3) HR for IS for Patients Diagnosed With ACS Between 2009 and 2010

  Other Risk Factors for IS After ACS           Adjusted HR (95% CI); *P* Value
  --------------------------------------------- ---------------------------------
  Age (per 10 years)                            1.25 (1.20--1.32); *P*\<0.001
  Female                                        1.24 (1.13--1.36); *P*\<0.001
  Race and ethnicity                            
  Black (compared with non‐Hispanic white)      1.70 (1.45--1.99); *P*\<0.001
  Hispanic (compared with non‐Hispanic white)   1.48 (1.29--1.75); *P*\<0.001
  Asian (compared with non‐Hispanic white)      1.25 (1.10--1.41); *P*\<0.001
  Insurance status                              
  Private insurance (compared with Medicare)    0.74 (0.64--0.85); *P*\<0.001
  Chronic kidney disease                        1.15 (1.02--1.31); *P*=0.0248
  Diabetes                                      1.30 (1.18--1.43); *P*\<0.001
  Hyperlipidemia                                0.72 (0.62--0.84); *P*\<0.001
  Atrial fibrillation                           1.58 (1.39--1.80); *P*\<0.001
  Congestive heart failure                      1.38 (1.25--1.53); *P*\<0.001

ACS indicates acute coronary syndrome; HR, hazard ratio; IS, ischemic stroke.

Discussion {#jah31594-sec-0018}
==========

The long‐term risk of IS after MI in our cohort was relatively low (2.7% at 2 years), which is likely related to the aggressive use of antiplatelet agents, reperfusion therapies, and statins after an acute coronary event.[4](#jah31594-bib-0004){ref-type="ref"} This is consistent with what has been reported in prior studies.[1](#jah31594-bib-0001){ref-type="ref"}, [4](#jah31594-bib-0004){ref-type="ref"} This risk, however, is ≈4‐fold higher in the presence of cardiac injury, such as STEMI and NSTEMI, as opposed to the absence of cardiac injury, such as in UA. In addition, unlike prior studies, our study demonstrated that NSTEMI conferred a similarly increased risk of IS as STEMI. The fact that the risk for STEMI is less affected by adjusting for other risk factors may suggest that direct cardiac mechanisms may be more likely after STEMI, whereas residual confounding or other mechanisms may play a role in at least some of the NSTEMI strokes. When stroke or death was used as a combined outcome, patients with STEMI had the highest risk, followed by NSTEMI and UA. This was not an unexpected finding, given the higher mortality rate after STEMI versus NSTEMI.[13](#jah31594-bib-0013){ref-type="ref"}, [14](#jah31594-bib-0014){ref-type="ref"} As in patients with STEMI, in our study, most IS in patients with NSTEMI occurred in the early period after the coronary event. In fact, our results suggest that the time period in which the risk of IS was elevated was in the first 6 months after the event. After 1 year, the risk of IS after UA becomes significantly higher than that of STEMI and NSTEMI. The reason for this is unclear; however, it is likely that patients with STEMI and NSTEMI who remain stroke free after 1 year may be at an inherently lower risk of IS.

The risk factors for IS after ACS in our study were age, female sex, CHF, diabetes, and AF, which were similar to those reported in prior studies.[1](#jah31594-bib-0001){ref-type="ref"}, [4](#jah31594-bib-0004){ref-type="ref"} Interestingly, these risk factors are also risk factors for embolism in patients with AF[15](#jah31594-bib-0015){ref-type="ref"}; therefore, they either may increase the risk of formation of cardiac thrombi after MI or may lead to cerebrovascular atherosclerosis and IS risk.

Mechanism of Risk and Clinical Implications {#jah31594-sec-0019}
-------------------------------------------

The relationship between cardiac injury in ACS and long‐term IS risk may be related to several potential mechanisms. Cardiac injury may lead to cardiac dysfunction and hypokinesis of cardiac chambers, which in turn may predispose the patient to thrombus formation[16](#jah31594-bib-0016){ref-type="ref"}, [17](#jah31594-bib-0017){ref-type="ref"}, [18](#jah31594-bib-0018){ref-type="ref"} and embolism. In addition, cardiac injury may cause atrial dysfunction or cardiopathy, which portends an increased risk of IS even in the absence of AF,[19](#jah31594-bib-0019){ref-type="ref"}, [20](#jah31594-bib-0020){ref-type="ref"}, [21](#jah31594-bib-0021){ref-type="ref"}, [22](#jah31594-bib-0022){ref-type="ref"}, [23](#jah31594-bib-0023){ref-type="ref"}, [24](#jah31594-bib-0024){ref-type="ref"}, [25](#jah31594-bib-0025){ref-type="ref"} or may induce atrial arrhythmias such as AF, which in turn may lead to an increased risk of IS. Last, cardiac injury in ACS may be a marker of severe systemic and cerebrovascular atherosclerotic disease that in turn is associated with IS risk.

Our study has several clinical implications. Because both NSTEMI and STEMI confer a similarly elevated risk of stroke compared with that of patients with UA, studies to better understand stroke mechanisms in these patients are necessary to potentially improve stroke prevention strategies. The use of long‐term outpatient monitoring in these patients, for example, may improve detection of AF and lead to improved stroke prevention strategies. Furthermore, because cardiac injury may be a marker of cerebrovascular disease, evaluating these patients for cerebrovascular disease may improve stroke prevention strategies in these patients.

Strengths and Limitations {#jah31594-sec-0020}
-------------------------

Our study has several limitations including lack of data on the location of MI, echocardiographic findings, relatively short‐term follow‐up, and use of ICD‐9 codes that may be subject to error. These codes, however, have been used and validated in prior studies using the same data set.[7](#jah31594-bib-0007){ref-type="ref"}, [8](#jah31594-bib-0008){ref-type="ref"}, [9](#jah31594-bib-0009){ref-type="ref"} In addition, we lacked data on medications used and stroke mechanisms after ACS that may limit both our understanding of the stroke risk and our ability to recommend stroke prevention strategies. Furthermore, this study included patients who were hospitalized at nonfederal hospitals in the state of California; therefore, hospitalizations outside the state of California were not captured in the database. Although this may potentially underestimate the risk of IS after ACS, it would not necessarily lead to a differential increase in ischemic risk in one category of ACS over the others. Moreover, our study has several strengths, including a large sample size with a wide variety of hospital settings, making our results more generalizable.

Conclusion {#jah31594-sec-0021}
==========

NSTEMI and STEMI conferred equally increased risks of IS compared with UA. Studies exploring IS mechanisms in these patient groups are needed to improve and tailor stroke prevention strategies.
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